Etamsylate + Tranexamic AcidThird Party Manufacturing in India

Etamsylate + Tranexamic Acid combines two distinct but complementary hemostatic mechanisms to provide comprehensive control of bleeding through both vascular and fibrinolytic pathways. Etamsylate, a systemic hemostatic agent also known as ethamsylate, works primarily at the vascular level by increasing platelet adhesion to the endothelium of damaged capillaries and restoring capillary resistance. It achieves this by inhibiting the biosynthesis and action of prostaglandins that cause platelet disaggregation, vasodilation, and increased capillary permeability. Specifically, etamsylate reduces the production of prostacyclin in the vascular endothelium, which normally inhibits platelet aggregation, thereby promoting platelet plug formation at sites of vascular injury. It also enhances the release of platelet factor 3 and factor 4, contributing to the coagulation cascade amplification. Tranexamic acid, a synthetic derivative of the amino acid lysine, works through an entirely different but synergistic mechanism as an antifibrinolytic agent. It competitively and reversibly inhibits the activation of plasminogen to plasmin by binding to four to five lysine receptor sites on plasminogen, blocking its interaction with fibrin. By preventing plasmin formation, tranexamic acid protects fibrin clots from enzymatic degradation by plasmin, preserving the structural integrity of the hemostatic plug. This dual-action approach ensures that bleeding is controlled both by improving primary hemostasis at the capillary level and by preventing premature clot breakdown, providing effective management of capillary and hemorrhagic conditions.

Therapeutic Uses

Etamsylate + Tranexamic Acid is prescribed for:

• Menorrhagia: For the treatment of heavy menstrual bleeding, where the combination helps reduce blood loss by improving capillary integrity and preventing fibrinolysis in the endometrial vasculature.
• Postoperative Bleeding: For the prophylaxis and control of hemorrhage following surgical procedures including dental surgery, ENT surgery, urological surgery, and gynecological procedures where capillary bleeding and impaired hemostasis are concerns.
• Capillary Bleeding Disorders: For the management of capillary bleeding of various etiologies including epistaxis, gingival bleeding, hematuria, and bleeding associated with thrombocytopenia or thrombocytopathia.
• Obstetric and Gynecological Hemorrhage: As adjunctive therapy in obstetric hemorrhage and metrorrhagia where both improved platelet function and antifibrinolytic activity are clinically beneficial.

Why Manufacturers Choose This Combination

The Etamsylate + Tranexamic Acid combination is a widely prescribed hemostatic formulation in the Indian pharmaceutical market, particularly in the gynecology and surgical specialties where control of bleeding is a primary clinical concern. The combination addresses two key mechanisms of hemostasis simultaneously, offering a more comprehensive approach to bleeding management than either agent alone. The fixed-dose tablet format of 250mg plus 250mg provides convenient twice or thrice daily dosing for adults. In the Indian context, this combination is routinely prescribed in obstetrics and gynecology for menorrhagia management, in dental practice for post-extraction bleeding, and in ENT practice for epistaxis control, ensuring broad clinical adoption across multiple specialties. For PCD franchise operators, the hemostatic category offers a specialized product with consistent prescription demand from general practitioners, gynecologists, and surgeons. Indian WHO-GMP certified third party manufacturers produce this combination for both domestic distribution and export to markets across Africa and Southeast Asia where affordable hemostatic formulations are in high demand for hospital formularies.

This makes Etamsylate + Tranexamic Acid a clinically important combination for third party manufacturing in India, with sustained demand from PCD franchise networks and institutional hospital supplies.